Many modules are hidden in this stack. Use "module --show_hidden spider SOFTWARE" if you are not able to find the required software
# packages in environment at /cluster/home/gcardenal/miniconda3/envs/vllm:
#
# Name                    Version                   Build  Channel
_libgcc_mutex             0.1                        main  
_openmp_mutex             5.1                       1_gnu  
accelerate                1.1.1                    pypi_0    pypi
aiohappyeyeballs          2.4.0                    pypi_0    pypi
aiohttp                   3.10.6                   pypi_0    pypi
aiosignal                 1.3.1                    pypi_0    pypi
annotated-types           0.7.0                    pypi_0    pypi
anthropic                 0.40.0                   pypi_0    pypi
anyio                     4.6.0                    pypi_0    pypi
argon2-cffi               23.1.0                   pypi_0    pypi
argon2-cffi-bindings      21.2.0                   pypi_0    pypi
arrow                     1.3.0                    pypi_0    pypi
asttokens                 3.0.0                    pypi_0    pypi
async-lru                 2.0.4                    pypi_0    pypi
async-timeout             4.0.3                    pypi_0    pypi
attrs                     24.2.0                   pypi_0    pypi
babel                     2.16.0                   pypi_0    pypi
beautifulsoup4            4.12.3                   pypi_0    pypi
bleach                    6.2.0                    pypi_0    pypi
bzip2                     1.0.8                h5eee18b_6  
ca-certificates           2024.7.2             h06a4308_0  
certifi                   2024.8.30                pypi_0    pypi
cffi                      1.17.1                   pypi_0    pypi
charset-normalizer        3.3.2                    pypi_0    pypi
click                     8.1.7                    pypi_0    pypi
cloudpickle               3.0.0                    pypi_0    pypi
comm                      0.2.2                    pypi_0    pypi
datasets                  3.0.1                    pypi_0    pypi
debugpy                   1.8.9                    pypi_0    pypi
decorator                 5.1.1                    pypi_0    pypi
defusedxml                0.7.1                    pypi_0    pypi
dill                      0.3.8                    pypi_0    pypi
diskcache                 5.6.3                    pypi_0    pypi
distro                    1.9.0                    pypi_0    pypi
einops                    0.8.0                    pypi_0    pypi
emoji                     2.14.0                   pypi_0    pypi
exceptiongroup            1.2.2                    pypi_0    pypi
executing                 2.1.0                    pypi_0    pypi
fastapi                   0.115.0                  pypi_0    pypi
fastjsonschema            2.21.1                   pypi_0    pypi
filelock                  3.16.1                   pypi_0    pypi
fqdn                      1.5.1                    pypi_0    pypi
frozenlist                1.4.1                    pypi_0    pypi
fsspec                    2024.6.1                 pypi_0    pypi
gguf                      0.10.0                   pypi_0    pypi
h11                       0.14.0                   pypi_0    pypi
httpcore                  1.0.5                    pypi_0    pypi
httptools                 0.6.1                    pypi_0    pypi
httpx                     0.27.2                   pypi_0    pypi
huggingface-hub           0.25.1                   pypi_0    pypi
idna                      3.10                     pypi_0    pypi
importlib-metadata        8.5.0                    pypi_0    pypi
interegular               0.3.3                    pypi_0    pypi
ipykernel                 6.29.5                   pypi_0    pypi
ipython                   8.30.0                   pypi_0    pypi
ipywidgets                8.1.5                    pypi_0    pypi
isoduration               20.11.0                  pypi_0    pypi
jedi                      0.19.2                   pypi_0    pypi
jinja2                    3.1.4                    pypi_0    pypi
jiter                     0.5.0                    pypi_0    pypi
json5                     0.10.0                   pypi_0    pypi
jsonpointer               3.0.0                    pypi_0    pypi
jsonschema                4.23.0                   pypi_0    pypi
jsonschema-specifications 2023.12.1                pypi_0    pypi
jupyter                   1.1.1                    pypi_0    pypi
jupyter-client            8.6.3                    pypi_0    pypi
jupyter-console           6.6.3                    pypi_0    pypi
jupyter-core              5.7.2                    pypi_0    pypi
jupyter-events            0.10.0                   pypi_0    pypi
jupyter-lsp               2.2.5                    pypi_0    pypi
jupyter-server            2.14.2                   pypi_0    pypi
jupyter-server-terminals  0.5.3                    pypi_0    pypi
jupyterlab                4.3.2                    pypi_0    pypi
jupyterlab-pygments       0.3.0                    pypi_0    pypi
jupyterlab-server         2.27.3                   pypi_0    pypi
jupyterlab-widgets        3.0.13                   pypi_0    pypi
lark                      1.2.2                    pypi_0    pypi
ld_impl_linux-64          2.40                 h12ee557_0  
libffi                    3.4.4                h6a678d5_1  
libgcc-ng                 11.2.0               h1234567_1  
libgomp                   11.2.0               h1234567_1  
libstdcxx-ng              11.2.0               h1234567_1  
libuuid                   1.41.5               h5eee18b_0  
llvmlite                  0.43.0                   pypi_0    pypi
lm-format-enforcer        0.10.6                   pypi_0    pypi
markupsafe                2.1.5                    pypi_0    pypi
matplotlib-inline         0.1.7                    pypi_0    pypi
mistral-common            1.4.3                    pypi_0    pypi
mistune                   3.0.2                    pypi_0    pypi
mpmath                    1.3.0                    pypi_0    pypi
msgpack                   1.1.0                    pypi_0    pypi
msgspec                   0.18.6                   pypi_0    pypi
multidict                 6.1.0                    pypi_0    pypi
multiprocess              0.70.16                  pypi_0    pypi
nbclient                  0.10.1                   pypi_0    pypi
nbconvert                 7.16.4                   pypi_0    pypi
nbformat                  5.10.4                   pypi_0    pypi
ncurses                   6.4                  h6a678d5_0  
nest-asyncio              1.6.0                    pypi_0    pypi
networkx                  3.3                      pypi_0    pypi
notebook                  7.3.1                    pypi_0    pypi
notebook-shim             0.2.4                    pypi_0    pypi
numba                     0.60.0                   pypi_0    pypi
numpy                     1.26.4                   pypi_0    pypi
nvidia-cublas-cu12        12.1.3.1                 pypi_0    pypi
nvidia-cuda-cupti-cu12    12.1.105                 pypi_0    pypi
nvidia-cuda-nvrtc-cu12    12.1.105                 pypi_0    pypi
nvidia-cuda-runtime-cu12  12.1.105                 pypi_0    pypi
nvidia-cudnn-cu12         9.1.0.70                 pypi_0    pypi
nvidia-cufft-cu12         11.0.2.54                pypi_0    pypi
nvidia-curand-cu12        10.3.2.106               pypi_0    pypi
nvidia-cusolver-cu12      11.4.5.107               pypi_0    pypi
nvidia-cusparse-cu12      12.1.0.106               pypi_0    pypi
nvidia-ml-py              12.560.30                pypi_0    pypi
nvidia-nccl-cu12          2.20.5                   pypi_0    pypi
nvidia-nvjitlink-cu12     12.6.68                  pypi_0    pypi
nvidia-nvtx-cu12          12.1.105                 pypi_0    pypi
openai                    1.48.0                   pypi_0    pypi
openssl                   3.0.15               h5eee18b_0  
outlines                  0.0.46                   pypi_0    pypi
overrides                 7.7.0                    pypi_0    pypi
packaging                 24.1                     pypi_0    pypi
pandas                    2.2.3                    pypi_0    pypi
pandocfilters             1.5.1                    pypi_0    pypi
parso                     0.8.4                    pypi_0    pypi
partial-json-parser       0.2.1.1.post4            pypi_0    pypi
pexpect                   4.9.0                    pypi_0    pypi
pillow                    10.4.0                   pypi_0    pypi
pip                       24.2            py310h06a4308_0  
platformdirs              4.3.6                    pypi_0    pypi
plotly                    5.24.1                   pypi_0    pypi
prometheus-client         0.21.0                   pypi_0    pypi
prometheus-fastapi-instrumentator 7.0.0                    pypi_0    pypi
prompt-toolkit            3.0.48                   pypi_0    pypi
protobuf                  5.28.2                   pypi_0    pypi
psutil                    6.0.0                    pypi_0    pypi
ptyprocess                0.7.0                    pypi_0    pypi
pure-eval                 0.2.3                    pypi_0    pypi
py-cpuinfo                9.0.0                    pypi_0    pypi
pyairports                2.1.1                    pypi_0    pypi
pyarrow                   17.0.0                   pypi_0    pypi
pycountry                 24.6.1                   pypi_0    pypi
pycparser                 2.22                     pypi_0    pypi
pydantic                  2.9.2                    pypi_0    pypi
pydantic-core             2.23.4                   pypi_0    pypi
pygments                  2.18.0                   pypi_0    pypi
python                    3.10.14              h955ad1f_1  
python-dateutil           2.9.0.post0              pypi_0    pypi
python-dotenv             1.0.1                    pypi_0    pypi
python-json-logger        2.0.7                    pypi_0    pypi
pytz                      2024.2                   pypi_0    pypi
pyyaml                    6.0.2                    pypi_0    pypi
pyzmq                     26.2.0                   pypi_0    pypi
ray                       2.37.0                   pypi_0    pypi
readline                  8.2                  h5eee18b_0  
referencing               0.35.1                   pypi_0    pypi
regex                     2024.9.11                pypi_0    pypi
requests                  2.32.3                   pypi_0    pypi
rfc3339-validator         0.1.4                    pypi_0    pypi
rfc3986-validator         0.1.1                    pypi_0    pypi
rpds-py                   0.20.0                   pypi_0    pypi
safetensors               0.4.5                    pypi_0    pypi
send2trash                1.8.3                    pypi_0    pypi
sentencepiece             0.2.0                    pypi_0    pypi
setuptools                75.1.0          py310h06a4308_0  
six                       1.16.0                   pypi_0    pypi
sniffio                   1.3.1                    pypi_0    pypi
soupsieve                 2.6                      pypi_0    pypi
sqlite                    3.45.3               h5eee18b_0  
stack-data                0.6.3                    pypi_0    pypi
stanza                    1.9.2                    pypi_0    pypi
starlette                 0.38.6                   pypi_0    pypi
sympy                     1.13.3                   pypi_0    pypi
tenacity                  9.0.0                    pypi_0    pypi
terminado                 0.18.1                   pypi_0    pypi
tiktoken                  0.7.0                    pypi_0    pypi
timm                      1.0.12                   pypi_0    pypi
tinycss2                  1.4.0                    pypi_0    pypi
tk                        8.6.14               h39e8969_0  
tokenizers                0.20.0                   pypi_0    pypi
tomli                     2.2.1                    pypi_0    pypi
torch                     2.4.0                    pypi_0    pypi
torchvision               0.19.0                   pypi_0    pypi
tornado                   6.4.2                    pypi_0    pypi
tqdm                      4.66.5                   pypi_0    pypi
traitlets                 5.14.3                   pypi_0    pypi
transformers              4.45.0                   pypi_0    pypi
triton                    3.0.0                    pypi_0    pypi
types-python-dateutil     2.9.0.20241003           pypi_0    pypi
typing-extensions         4.12.2                   pypi_0    pypi
tzdata                    2024.2                   pypi_0    pypi
uri-template              1.3.0                    pypi_0    pypi
urllib3                   2.2.3                    pypi_0    pypi
uvicorn                   0.30.6                   pypi_0    pypi
uvloop                    0.20.0                   pypi_0    pypi
vllm                      0.6.2                    pypi_0    pypi
watchfiles                0.24.0                   pypi_0    pypi
wcwidth                   0.2.13                   pypi_0    pypi
webcolors                 24.11.1                  pypi_0    pypi
webencodings              0.5.1                    pypi_0    pypi
websocket-client          1.8.0                    pypi_0    pypi
websockets                13.1                     pypi_0    pypi
wheel                     0.44.0          py310h06a4308_0  
widgetsnbextension        4.0.13                   pypi_0    pypi
xformers                  0.0.27.post2             pypi_0    pypi
xxhash                    3.5.0                    pypi_0    pypi
xz                        5.4.6                h5eee18b_1  
yarl                      1.12.1                   pypi_0    pypi
zipp                      3.20.2                   pypi_0    pypi
zlib                      1.2.13               h5eee18b_1  
Package                           Version
--------------------------------- --------------
accelerate                        1.1.1
aiohappyeyeballs                  2.4.0
aiohttp                           3.10.6
aiosignal                         1.3.1
annotated-types                   0.7.0
anthropic                         0.40.0
anyio                             4.6.0
argon2-cffi                       23.1.0
argon2-cffi-bindings              21.2.0
arrow                             1.3.0
asttokens                         3.0.0
async-lru                         2.0.4
async-timeout                     4.0.3
attrs                             24.2.0
babel                             2.16.0
beautifulsoup4                    4.12.3
bleach                            6.2.0
certifi                           2024.8.30
cffi                              1.17.1
charset-normalizer                3.3.2
click                             8.1.7
cloudpickle                       3.0.0
comm                              0.2.2
datasets                          3.0.1
debugpy                           1.8.9
decorator                         5.1.1
defusedxml                        0.7.1
dill                              0.3.8
diskcache                         5.6.3
distro                            1.9.0
einops                            0.8.0
emoji                             2.14.0
exceptiongroup                    1.2.2
executing                         2.1.0
fastapi                           0.115.0
fastjsonschema                    2.21.1
filelock                          3.16.1
fqdn                              1.5.1
frozenlist                        1.4.1
fsspec                            2024.6.1
gguf                              0.10.0
h11                               0.14.0
httpcore                          1.0.5
httptools                         0.6.1
httpx                             0.27.2
huggingface-hub                   0.25.1
idna                              3.10
importlib_metadata                8.5.0
interegular                       0.3.3
ipykernel                         6.29.5
ipython                           8.30.0
ipywidgets                        8.1.5
isoduration                       20.11.0
jedi                              0.19.2
Jinja2                            3.1.4
jiter                             0.5.0
json5                             0.10.0
jsonpointer                       3.0.0
jsonschema                        4.23.0
jsonschema-specifications         2023.12.1
jupyter                           1.1.1
jupyter_client                    8.6.3
jupyter-console                   6.6.3
jupyter_core                      5.7.2
jupyter-events                    0.10.0
jupyter-lsp                       2.2.5
jupyter_server                    2.14.2
jupyter_server_terminals          0.5.3
jupyterlab                        4.3.2
jupyterlab_pygments               0.3.0
jupyterlab_server                 2.27.3
jupyterlab_widgets                3.0.13
lark                              1.2.2
llvmlite                          0.43.0
lm-format-enforcer                0.10.6
MarkupSafe                        2.1.5
matplotlib-inline                 0.1.7
mistral_common                    1.4.3
mistune                           3.0.2
mpmath                            1.3.0
msgpack                           1.1.0
msgspec                           0.18.6
multidict                         6.1.0
multiprocess                      0.70.16
nbclient                          0.10.1
nbconvert                         7.16.4
nbformat                          5.10.4
nest-asyncio                      1.6.0
networkx                          3.3
notebook                          7.3.1
notebook_shim                     0.2.4
numba                             0.60.0
numpy                             1.26.4
nvidia-cublas-cu12                12.1.3.1
nvidia-cuda-cupti-cu12            12.1.105
nvidia-cuda-nvrtc-cu12            12.1.105
nvidia-cuda-runtime-cu12          12.1.105
nvidia-cudnn-cu12                 9.1.0.70
nvidia-cufft-cu12                 11.0.2.54
nvidia-curand-cu12                10.3.2.106
nvidia-cusolver-cu12              11.4.5.107
nvidia-cusparse-cu12              12.1.0.106
nvidia-ml-py                      12.560.30
nvidia-nccl-cu12                  2.20.5
nvidia-nvjitlink-cu12             12.6.68
nvidia-nvtx-cu12                  12.1.105
openai                            1.48.0
outlines                          0.0.46
overrides                         7.7.0
packaging                         24.1
pandas                            2.2.3
pandocfilters                     1.5.1
parso                             0.8.4
partial-json-parser               0.2.1.1.post4
pexpect                           4.9.0
pillow                            10.4.0
pip                               24.2
platformdirs                      4.3.6
plotly                            5.24.1
prometheus_client                 0.21.0
prometheus-fastapi-instrumentator 7.0.0
prompt_toolkit                    3.0.48
protobuf                          5.28.2
psutil                            6.0.0
ptyprocess                        0.7.0
pure_eval                         0.2.3
py-cpuinfo                        9.0.0
pyairports                        2.1.1
pyarrow                           17.0.0
pycountry                         24.6.1
pycparser                         2.22
pydantic                          2.9.2
pydantic_core                     2.23.4
Pygments                          2.18.0
python-dateutil                   2.9.0.post0
python-dotenv                     1.0.1
python-json-logger                2.0.7
pytz                              2024.2
PyYAML                            6.0.2
pyzmq                             26.2.0
ray                               2.37.0
referencing                       0.35.1
regex                             2024.9.11
requests                          2.32.3
rfc3339-validator                 0.1.4
rfc3986-validator                 0.1.1
rpds-py                           0.20.0
safetensors                       0.4.5
Send2Trash                        1.8.3
sentencepiece                     0.2.0
setuptools                        75.1.0
six                               1.16.0
sniffio                           1.3.1
soupsieve                         2.6
stack-data                        0.6.3
stanza                            1.9.2
starlette                         0.38.6
sympy                             1.13.3
tenacity                          9.0.0
terminado                         0.18.1
tiktoken                          0.7.0
timm                              1.0.12
tinycss2                          1.4.0
tokenizers                        0.20.0
tomli                             2.2.1
torch                             2.4.0
torchvision                       0.19.0
tornado                           6.4.2
tqdm                              4.66.5
traitlets                         5.14.3
transformers                      4.45.0
triton                            3.0.0
types-python-dateutil             2.9.0.20241003
typing_extensions                 4.12.2
tzdata                            2024.2
uri-template                      1.3.0
urllib3                           2.2.3
uvicorn                           0.30.6
uvloop                            0.20.0
vllm                              0.6.2
watchfiles                        0.24.0
wcwidth                           0.2.13
webcolors                         24.11.1
webencodings                      0.5.1
websocket-client                  1.8.0
websockets                        13.1
wheel                             0.44.0
widgetsnbextension                4.0.13
xformers                          0.0.27.post2
xxhash                            3.5.0
yarl                              1.12.1
zipp                              3.20.2

Currently Loaded Modules:
  1) eth_proxy      4) stack/2024-06   7) python/3.11.6  10) openblas/0.3.24
  2) julia/1.10.3   5) r/4.3.2         8) cuda/12.1.1    11) python_cuda/3.11.6
  3) gcc/12.2.0     6) hdf5/1.14.3     9) nccl/2.18.3-1

 

Testing Slurm Variables...
SLURM_JOB_USER=gcardenal
SLURM_TASKS_PER_NODE=1
SLURM_JOB_UID=608619
SLURM_TASK_PID=3617930
SLURM_JOB_GPUS=1,3,4
SLURM_LOCALID=0
SLURM_SUBMIT_DIR=/cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation
SLURMD_NODENAME=eu-a65-06
SLURM_JOB_START_TIME=1737209048
SLURM_CLUSTER_NAME=euler-24-production
SLURM_JOB_END_TIME=1737223448
SLURM_CPUS_ON_NODE=8
SLURM_JOB_CPUS_PER_NODE=8
SLURM_GPUS_ON_NODE=3
SLURM_GTIDS=0
SLURM_JOB_PARTITION=gpupr.4h
SLURM_TRES_PER_TASK=cpu=8
SLURM_JOB_NUM_NODES=1
SLURM_JOBID=21171624
SLURM_GPUS=nvidia_a100_80gb_pcie:3
SLURM_JOB_QOS=es_ilic/gpupr/4
SLURM_PROCID=0
SLURM_CPUS_PER_TASK=8
SLURM_NTASKS=1
SLURM_TOPOLOGY_ADDR=.euler_a100_80_lca_ib.eu-a65-06
SLURM_TOPOLOGY_ADDR_PATTERN=switch.switch.node
SLURM_MEM_PER_CPU=10240
SLURM_SCRIPT_CONTEXT=prolog_task
SLURM_NODELIST=eu-a65-06
SLURM_JOB_ACCOUNT=gpupr/es_ilic
SLURM_PRIO_PROCESS=0
SLURM_NPROCS=1
SLURM_NNODES=1
SLURM_SUBMIT_HOST=eu-g5-030-1
SLURM_JOB_ID=21171624
SLURM_NODEID=0
SLURM_CONF=/cluster/slurm/adm/etc/slurm.conf
SLURM_JOB_NAME=llama_no_api
SLURM_JOB_GID=492010
SLURM_JOB_NODELIST=eu-a65-06
Sat Jan 18 15:04:21 2025       
+-----------------------------------------------------------------------------------------+
| NVIDIA-SMI 550.127.08             Driver Version: 550.127.08     CUDA Version: 12.4     |
|-----------------------------------------+------------------------+----------------------+
| GPU  Name                 Persistence-M | Bus-Id          Disp.A | Volatile Uncorr. ECC |
| Fan  Temp   Perf          Pwr:Usage/Cap |           Memory-Usage | GPU-Util  Compute M. |
|                                         |                        |               MIG M. |
|=========================================+========================+======================|
|   0  NVIDIA A100 80GB PCIe          On  |   00000000:08:00.0 Off |                    0 |
| N/A   30C    P0             43W /  300W |       1MiB /  81920MiB |      0%      Default |
|                                         |                        |             Disabled |
+-----------------------------------------+------------------------+----------------------+
|   1  NVIDIA A100 80GB PCIe          On  |   00000000:48:00.0 Off |                    0 |
| N/A   30C    P0             40W /  300W |       1MiB /  81920MiB |      0%      Default |
|                                         |                        |             Disabled |
+-----------------------------------------+------------------------+----------------------+
|   2  NVIDIA A100 80GB PCIe          On  |   00000000:4C:00.0 Off |                    0 |
| N/A   30C    P0             42W /  300W |       1MiB /  81920MiB |      0%      Default |
|                                         |                        |             Disabled |
+-----------------------------------------+------------------------+----------------------+
                                                                                         
+-----------------------------------------------------------------------------------------+
| Processes:                                                                              |
|  GPU   GI   CI        PID   Type   Process name                              GPU Memory |
|        ID   ID                                                               Usage      |
|=========================================================================================|
|  No running processes found                                                             |
+-----------------------------------------------------------------------------------------+
Node IP: 10.205.9.15
JobId=21171624 JobName=llama_no_api
   UserId=gcardenal(608619) GroupId=gcardenal-group(492010) MCS_label=N/A
   Priority=5806 Nice=0 Account=gpupr/es_ilic QOS=es_ilic/gpupr/4
   JobState=RUNNING Reason=None Dependency=(null)
   Requeue=0 Restarts=0 BatchFlag=1 Reboot=0 ExitCode=0:0
   RunTime=00:00:14 TimeLimit=04:00:00 TimeMin=N/A
   SubmitTime=2025-01-18T15:04:08 EligibleTime=2025-01-18T15:04:08
   AccrueTime=2025-01-18T15:04:08
   StartTime=2025-01-18T15:04:08 EndTime=2025-01-18T19:04:08 Deadline=N/A
   SuspendTime=None SecsPreSuspend=0 LastSchedEval=2025-01-18T15:04:08 Scheduler=Main
   Partition=gpupr.4h AllocNode:Sid=eu-g5-030-1:391019
   ReqNodeList=(null) ExcNodeList=(null)
   NodeList=eu-a65-06
   BatchHost=eu-a65-06
   NumNodes=1 NumCPUs=8 NumTasks=1 CPUs/Task=8 ReqB:S:C:T=0:0:*:*
   ReqTRES=cpu=8,mem=80G,node=1,billing=347340,gres/gpu=3,gres/gpu:nvidia_a100_80gb_pcie=3,gres/gpumem=85899345920
   AllocTRES=cpu=8,mem=80G,node=1,billing=347340,gres/gpu=3,gres/gpu:nvidia_a100_80gb_pcie=3,gres/gpumem=0
   Socks/Node=* NtasksPerN:B:S:C=0:0:*:1 CoreSpec=*
   MinCPUsNode=8 MinMemoryCPU=10G MinTmpDiskNode=0
   Features=(null) DelayBoot=00:00:00
   OverSubscribe=OK Contiguous=0 Licenses=(null) Network=(null)
   Command=/cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/generate_answers.sh
   WorkDir=/cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation
   StdErr=/cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/llama_no_api21171624.out
   StdIn=/dev/null
   StdOut=/cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/llama_no_api21171624.out
   TresPerJob=gres/gpu:nvidia_a100_80gb_pcie:3
   TresPerNode=gres/gpumem:80G
   TresPerTask=cpu=8
   

Running in standalone mode...
I0118 15:04:26.209000 22878650922816 torch/distributed/run.py:859] 
I0118 15:04:26.209000 22878650922816 torch/distributed/run.py:859] **************************************
I0118 15:04:26.209000 22878650922816 torch/distributed/run.py:859] Rendezvous info:
I0118 15:04:26.209000 22878650922816 torch/distributed/run.py:859] --rdzv-backend=c10d --rdzv-endpoint=localhost:0 --rdzv-id=854f08f1-b430-4dde-b67b-cebb2d0db4ef
I0118 15:04:26.209000 22878650922816 torch/distributed/run.py:859] **************************************
I0118 15:04:26.209000 22878650922816 torch/distributed/run.py:859] 
I0118 15:04:26.210000 22878650922816 torch/distributed/launcher/api.py:188] Starting elastic_operator with launch configs:
I0118 15:04:26.210000 22878650922816 torch/distributed/launcher/api.py:188]   entrypoint       : get_model_answers_and_prompt_generation.py
I0118 15:04:26.210000 22878650922816 torch/distributed/launcher/api.py:188]   min_nodes        : 1
I0118 15:04:26.210000 22878650922816 torch/distributed/launcher/api.py:188]   max_nodes        : 1
I0118 15:04:26.210000 22878650922816 torch/distributed/launcher/api.py:188]   nproc_per_node   : 1
I0118 15:04:26.210000 22878650922816 torch/distributed/launcher/api.py:188]   run_id           : 854f08f1-b430-4dde-b67b-cebb2d0db4ef
I0118 15:04:26.210000 22878650922816 torch/distributed/launcher/api.py:188]   rdzv_backend     : c10d
I0118 15:04:26.210000 22878650922816 torch/distributed/launcher/api.py:188]   rdzv_endpoint    : localhost:0
I0118 15:04:26.210000 22878650922816 torch/distributed/launcher/api.py:188]   rdzv_configs     : {'timeout': 900}
I0118 15:04:26.210000 22878650922816 torch/distributed/launcher/api.py:188]   max_restarts     : 0
I0118 15:04:26.210000 22878650922816 torch/distributed/launcher/api.py:188]   monitor_interval : 5
I0118 15:04:26.210000 22878650922816 torch/distributed/launcher/api.py:188]   log_dir          : /scratch/tmp.21171624.gcardenal/torchelastic_xg1nk2vy
I0118 15:04:26.210000 22878650922816 torch/distributed/launcher/api.py:188]   metrics_cfg      : {}
I0118 15:04:26.210000 22878650922816 torch/distributed/launcher/api.py:188] 
I0118 15:04:26.217000 22878650922816 torch/distributed/elastic/agent/server/api.py:866] [default] starting workers for entrypoint: python3
I0118 15:04:26.217000 22878650922816 torch/distributed/elastic/agent/server/api.py:699] [default] Rendezvous'ing worker group
I0118 15:04:26.523000 22878650922816 torch/distributed/elastic/agent/server/api.py:568] [default] Rendezvous complete for workers. Result:
I0118 15:04:26.523000 22878650922816 torch/distributed/elastic/agent/server/api.py:568]   restart_count=0
I0118 15:04:26.523000 22878650922816 torch/distributed/elastic/agent/server/api.py:568]   master_addr=eu-a65-06.euler.ethz.ch
I0118 15:04:26.523000 22878650922816 torch/distributed/elastic/agent/server/api.py:568]   master_port=39419
I0118 15:04:26.523000 22878650922816 torch/distributed/elastic/agent/server/api.py:568]   group_rank=0
I0118 15:04:26.523000 22878650922816 torch/distributed/elastic/agent/server/api.py:568]   group_world_size=1
I0118 15:04:26.523000 22878650922816 torch/distributed/elastic/agent/server/api.py:568]   local_ranks=[0]
I0118 15:04:26.523000 22878650922816 torch/distributed/elastic/agent/server/api.py:568]   role_ranks=[0]
I0118 15:04:26.523000 22878650922816 torch/distributed/elastic/agent/server/api.py:568]   global_ranks=[0]
I0118 15:04:26.523000 22878650922816 torch/distributed/elastic/agent/server/api.py:568]   role_world_sizes=[1]
I0118 15:04:26.523000 22878650922816 torch/distributed/elastic/agent/server/api.py:568]   global_world_sizes=[1]
I0118 15:04:26.523000 22878650922816 torch/distributed/elastic/agent/server/api.py:568] 
I0118 15:04:26.523000 22878650922816 torch/distributed/elastic/agent/server/api.py:707] [default] Starting worker group
I0118 15:04:26.523000 22878650922816 torch/distributed/elastic/agent/server/local_elastic_agent.py:168] Environment variable 'TORCHELASTIC_ENABLE_FILE_TIMER' not found. Do not start FileTimerServer.
I0118 15:04:26.523000 22878650922816 torch/distributed/elastic/multiprocessing/api.py:263] log directory set to: /scratch/tmp.21171624.gcardenal/torchelastic_xg1nk2vy/854f08f1-b430-4dde-b67b-cebb2d0db4ef_7c6dfq9g
I0118 15:04:26.523000 22878650922816 torch/distributed/elastic/multiprocessing/api.py:358] Setting worker0 reply file to: /scratch/tmp.21171624.gcardenal/torchelastic_xg1nk2vy/854f08f1-b430-4dde-b67b-cebb2d0db4ef_7c6dfq9g/attempt_0/0/error.json
2025-01-18 15:04:31.602673: E external/local_xla/xla/stream_executor/cuda/cuda_dnn.cc:9261] Unable to register cuDNN factory: Attempting to register factory for plugin cuDNN when one has already been registered
2025-01-18 15:04:31.602719: E external/local_xla/xla/stream_executor/cuda/cuda_fft.cc:607] Unable to register cuFFT factory: Attempting to register factory for plugin cuFFT when one has already been registered
2025-01-18 15:04:31.603969: E external/local_xla/xla/stream_executor/cuda/cuda_blas.cc:1515] Unable to register cuBLAS factory: Attempting to register factory for plugin cuBLAS when one has already been registered
2025-01-18 15:04:31.609540: I tensorflow/core/platform/cpu_feature_guard.cc:182] This TensorFlow binary is optimized to use available CPU instructions in performance-critical operations.
To enable the following instructions: AVX2 FMA, in other operations, rebuild TensorFlow with the appropriate compiler flags.
2025-01-18 15:04:32.830487: W tensorflow/compiler/tf2tensorrt/utils/py_utils.cc:38] TF-TRT Warning: Could not find TensorRT
Loading NVLM model...
/cluster/home/gcardenal/.local/lib/python3.11/site-packages/timm/models/layers/__init__.py:48: FutureWarning: Importing from timm.models.layers is deprecated, please import via timm.layers
  warnings.warn(f"Importing from {__name__} is deprecated, please import via timm.layers", FutureWarning)
/cluster/home/gcardenal/.local/lib/python3.11/site-packages/transformers/generation/configuration_utils.py:595: UserWarning: `do_sample` is set to `False`. However, `top_p` is set to `0` -- this flag is only used in sample-based generation modes. You should set `do_sample=True` or unset `top_p`. This was detected when initializing the generation config instance, which means the corresponding file may hold incorrect parameterization and should be fixed.
  warnings.warn(
/cluster/home/gcardenal/.local/lib/python3.11/site-packages/transformers/generation/configuration_utils.py:612: UserWarning: `do_sample` is set to `False`. However, `top_k` is set to `1` -- this flag is only used in sample-based generation modes. You should set `do_sample=True` or unset `top_k`. This was detected when initializing the generation config instance, which means the corresponding file may hold incorrect parameterization and should be fixed.
  warnings.warn(
/cluster/home/gcardenal/.local/lib/python3.11/site-packages/transformers/generation/configuration_utils.py:595: UserWarning: `do_sample` is set to `False`. However, `top_p` is set to `0` -- this flag is only used in sample-based generation modes. You should set `do_sample=True` or unset `top_p`.
  warnings.warn(
/cluster/home/gcardenal/.local/lib/python3.11/site-packages/transformers/generation/configuration_utils.py:612: UserWarning: `do_sample` is set to `False`. However, `top_k` is set to `1` -- this flag is only used in sample-based generation modes. You should set `do_sample=True` or unset `top_k`.
  warnings.warn(
Loading checkpoint shards:   0%|                                                              | 0/46 [00:00<?, ?it/s]Loading checkpoint shards:   2%|█▏                                                    | 1/46 [00:06<04:35,  6.12s/it]Loading checkpoint shards:   4%|██▎                                                   | 2/46 [01:14<31:17, 42.67s/it]Loading checkpoint shards:   7%|███▌                                                  | 3/46 [02:42<45:21, 63.28s/it]Loading checkpoint shards:   9%|████▍                                              | 4/46 [06:15<1:25:39, 122.38s/it]Loading checkpoint shards:  11%|█████▌                                             | 5/46 [09:42<1:44:28, 152.89s/it]Loading checkpoint shards:  13%|██████▋                                            | 6/46 [11:00<1:25:03, 127.59s/it]Loading checkpoint shards:  15%|███████▊                                           | 7/46 [11:47<1:05:44, 101.13s/it]Loading checkpoint shards:  17%|█████████▍                                            | 8/46 [12:08<48:01, 75.84s/it]Loading checkpoint shards:  20%|██████████▌                                           | 9/46 [13:43<50:19, 81.60s/it]Loading checkpoint shards:  22%|███████████▌                                         | 10/46 [13:59<36:50, 61.41s/it]Loading checkpoint shards:  24%|████████████▋                                        | 11/46 [14:26<29:39, 50.86s/it]Loading checkpoint shards:  26%|█████████████▊                                       | 12/46 [14:54<24:58, 44.07s/it]Loading checkpoint shards:  28%|██████████████▉                                      | 13/46 [15:30<22:54, 41.65s/it]Loading checkpoint shards:  30%|████████████████▏                                    | 14/46 [15:38<16:41, 31.30s/it]Loading checkpoint shards:  33%|█████████████████▎                                   | 15/46 [18:51<41:22, 80.09s/it]Loading checkpoint shards:  35%|██████████████████▍                                  | 16/46 [19:19<32:15, 64.50s/it]Loading checkpoint shards:  37%|███████████████████▌                                 | 17/46 [19:53<26:44, 55.33s/it]Loading checkpoint shards:  39%|████████████████████▋                                | 18/46 [20:27<22:46, 48.82s/it]Loading checkpoint shards:  41%|█████████████████████▉                               | 19/46 [21:21<22:41, 50.42s/it]Loading checkpoint shards:  43%|███████████████████████                              | 20/46 [21:57<19:55, 46.00s/it]Loading checkpoint shards:  46%|████████████████████████▏                            | 21/46 [22:16<15:47, 37.89s/it]Loading checkpoint shards:  48%|█████████████████████████▎                           | 22/46 [24:15<24:53, 62.21s/it]Loading checkpoint shards:  50%|██████████████████████████▌                          | 23/46 [24:57<21:36, 56.36s/it]Loading checkpoint shards:  52%|███████████████████████████▋                         | 24/46 [25:16<16:31, 45.06s/it]Loading checkpoint shards:  54%|████████████████████████████▊                        | 25/46 [26:49<20:45, 59.33s/it]Loading checkpoint shards:  57%|█████████████████████████████▉                       | 26/46 [27:12<16:12, 48.62s/it]Loading checkpoint shards:  59%|███████████████████████████████                      | 27/46 [27:52<14:30, 45.82s/it]Loading checkpoint shards:  61%|████████████████████████████████▎                    | 28/46 [28:35<13:32, 45.16s/it]Loading checkpoint shards:  63%|█████████████████████████████████▍                   | 29/46 [29:46<14:58, 52.87s/it]Loading checkpoint shards:  65%|██████████████████████████████████▌                  | 30/46 [30:24<12:54, 48.41s/it]Loading checkpoint shards:  67%|███████████████████████████████████▋                 | 31/46 [30:33<09:06, 36.45s/it]Loading checkpoint shards:  70%|████████████████████████████████████▊                | 32/46 [31:30<09:58, 42.72s/it]Loading checkpoint shards:  72%|██████████████████████████████████████               | 33/46 [31:38<06:58, 32.19s/it]Loading checkpoint shards:  74%|███████████████████████████████████████▏             | 34/46 [34:08<13:32, 67.67s/it]Loading checkpoint shards:  76%|████████████████████████████████████████▎            | 35/46 [34:28<09:46, 53.31s/it]Loading checkpoint shards:  78%|█████████████████████████████████████████▍           | 36/46 [34:59<07:45, 46.57s/it]Loading checkpoint shards:  80%|██████████████████████████████████████████▋          | 37/46 [35:11<05:27, 36.34s/it]Loading checkpoint shards:  83%|███████████████████████████████████████████▊         | 38/46 [35:28<04:04, 30.55s/it]Loading checkpoint shards:  85%|████████████████████████████████████████████▉        | 39/46 [36:32<04:44, 40.62s/it]Loading checkpoint shards:  87%|██████████████████████████████████████████████       | 40/46 [37:13<04:03, 40.63s/it]Loading checkpoint shards:  89%|███████████████████████████████████████████████▏     | 41/46 [39:05<05:09, 61.89s/it]Loading checkpoint shards:  91%|████████████████████████████████████████████████▍    | 42/46 [39:44<03:39, 55.00s/it]Loading checkpoint shards:  93%|█████████████████████████████████████████████████▌   | 43/46 [41:03<03:07, 62.44s/it]Loading checkpoint shards:  96%|██████████████████████████████████████████████████▋  | 44/46 [41:16<01:35, 47.54s/it]Loading checkpoint shards:  98%|███████████████████████████████████████████████████▊ | 45/46 [43:33<01:14, 74.31s/it]Loading checkpoint shards: 100%|█████████████████████████████████████████████████████| 46/46 [45:04<00:00, 79.21s/it]Loading checkpoint shards: 100%|█████████████████████████████████████████████████████| 46/46 [45:04<00:00, 58.78s/it]
Starting inference for question (NVLM): How is HIV diagnosed?
/cluster/home/gcardenal/.local/lib/python3.11/site-packages/transformers/generation/configuration_utils.py:595: UserWarning: `do_sample` is set to `False`. However, `top_p` is set to `0` -- this flag is only used in sample-based generation modes. You should set `do_sample=True` or unset `top_p`. This was detected when initializing the generation config instance, which means the corresponding file may hold incorrect parameterization and should be fixed.
  warnings.warn(
/cluster/home/gcardenal/.local/lib/python3.11/site-packages/transformers/generation/configuration_utils.py:612: UserWarning: `do_sample` is set to `False`. However, `top_k` is set to `1` -- this flag is only used in sample-based generation modes. You should set `do_sample=True` or unset `top_k`. This was detected when initializing the generation config instance, which means the corresponding file may hold incorrect parameterization and should be fixed.
  warnings.warn(
/cluster/home/gcardenal/.local/lib/python3.11/site-packages/transformers/generation/configuration_utils.py:595: UserWarning: `do_sample` is set to `False`. However, `top_p` is set to `0` -- this flag is only used in sample-based generation modes. You should set `do_sample=True` or unset `top_p`.
  warnings.warn(
/cluster/home/gcardenal/.local/lib/python3.11/site-packages/transformers/generation/configuration_utils.py:612: UserWarning: `do_sample` is set to `False`. However, `top_k` is set to `1` -- this flag is only used in sample-based generation modes. You should set `do_sample=True` or unset `top_k`.
  warnings.warn(
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
HIV (Human Immunodeficiency Virus) is typically diagnosed through a series of tests that detect the presence of the virus or its antibodies in the body. Here are the main steps involved in diagnosing HIV:

1. **Initial Screening Tests**:
   - **Antibody Tests**: These tests look for antibodies that the body produces in response to HIV. They can be done using blood, oral fluid, or urine samples. Common types include:
     - **Enzyme-Linked Immunosorbent Assay (ELISA)**: A blood test that detects HIV antibodies.
     - **Rapid Tests**: These provide results in about 20-30 minutes and can use blood, saliva, or urine.
   - **Antigen/Antibody Tests**: These tests can detect both antibodies and the p24 antigen (a protein produced by HIV) in the blood. They are more sensitive and can detect HIV earlier than antibody tests alone.

2. **Confirmatory Tests**:
   - If an initial screening test is positive, a confirmatory test is usually performed to verify the result. The most common confirmatory test is the **Western Blot** or **Immunofluorescence Assay (IFA)**, which provides more specific information about the antibodies present.

3. **Viral Load Tests**:
   - Once HIV is confirmed, viral load tests may be conducted to measure the amount of HIV RNA in the blood. This helps in assessing the severity of the infection and monitoring the effectiveness of treatment.

4. **CD4 Count**:
   - A CD4 count measures the number of CD4 cells (a type of white blood cell) in the blood. A low CD4 count indicates a weakened immune system and can help stage the HIV infection.

5. **Genotyping and Drug Resistance Testing**:
   - In some cases, especially for individuals starting antiretroviral therapy (ART), genotyping may be performed to determine the specific strain of HIV and identify any drug resistance.

6. **Follow-Up Testing**:
   - After diagnosis, regular monitoring with viral load and CD4 count tests is essential to track the progression of the disease and the effectiveness of treatment.

It's important to note that early diagnosis is crucial for effective management and treatment of HIV. If you think you may have been exposed to HIV, it's important to get tested as soon as possible.
Starting inference for question (NVLM): What are the different stages of HIV?
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
HIV (Human Immunodeficiency Virus) progresses through several stages, each with distinct characteristics. Understanding these stages is crucial for managing the infection and preventing its spread. Here are the main stages of HIV:

1. **Acute HIV Infection (Primary Infection)**:
   - This stage occurs within 2 to 4 weeks after initial exposure to the virus.
   - Many people experience flu-like symptoms, such as fever, fatigue, swollen lymph nodes, sore throat, and rash.
   - The virus replicates rapidly, and viral load (the amount of virus in the blood) is high.
   - The body begins to produce antibodies against HIV, a process known as seroconversion.

2. **Clinical Latency (Chronic HIV Infection)**:
   - After the acute stage, the virus enters a period of latency, which can last for many years.
   - During this stage, individuals may not experience any symptoms and can appear healthy.
   - HIV is still present in the body, but the viral load is lower, and the immune system is not severely compromised.
   - However, without treatment, the virus continues to replicate at low levels, gradually damaging the immune system.

3. **AIDS (Acquired Immunodeficiency Syndrome)**:
   - AIDS is the most advanced stage of HIV infection, characterized by a severely compromised immune system.
   - It is defined by a CD4 cell count (a type of white blood cell) of less than 200 cells/mm³ or the presence of certain opportunistic infections or cancers.
   - Common symptoms include weight loss, fever, night sweats, and increased susceptibility to infections.
   - Without treatment, individuals at this stage have a higher risk of life-threatening complications.

4. **HIV Treatment and Management**:
   - With the advent of antiretroviral therapy (ART), many individuals can manage HIV effectively, allowing them to live long, healthy lives.
   - Treatment can suppress the virus to undetectable levels, preventing progression to AIDS and reducing the risk of transmission to others.
   - Regular monitoring of viral load and CD4 cell count is essential to assess the effectiveness of treatment and the health of the immune system.

It's important to note that early diagnosis and treatment are crucial in managing HIV. Regular testing, especially for those at higher risk, is recommended to ensure timely intervention.
Starting inference for question (NVLM): How is HIV transmitted?
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
HIV (Human Immunodeficiency Virus) is primarily transmitted through certain bodily fluids from a person who has the virus. The main routes of transmission include:

1. **Unprotected Sexual Contact**: HIV can be transmitted through vaginal, anal, or oral sex without the use of protection (like condoms or dental dams). The risk is higher for receptive anal sex and vaginal sex.

2. **Sharing Needles**: Using needles, syringes, or other drug injection equipment that has been used by someone with HIV can transmit the virus.

3. **From Mother to Child**: HIV can be transmitted from an infected mother to her child during pregnancy, childbirth, or breastfeeding. However, with proper medical care, the risk of transmission can be significantly reduced.

4. **Blood Transfusion**: In some cases, HIV can be transmitted through blood transfusions or organ transplants, but this is rare in countries where blood supplies are screened for HIV.

5. **Accidental Needle Sticks**: Healthcare workers may be at risk of HIV transmission through accidental needle sticks or other sharp instrument injuries.

It is important to note that HIV cannot be transmitted through casual contact, such as hugging, shaking hands, or sharing food and drinks. The virus does not survive long outside the body, and it cannot be transmitted through air, water, or food.
Starting inference for question (NVLM): What comorbidities are common among people living 
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
People living with HIV (PLHIV) often experience a range of comorbidities, which are additional health conditions that occur alongside HIV. Some common comorbidities include:

1. **Cardiovascular Diseases**: Increased risk of heart disease, stroke, and other cardiovascular issues due to inflammation and metabolic changes associated with HIV and antiretroviral therapy.

2. **Liver Diseases**: Hepatitis B and C are common coinfections, as both viruses affect the liver and can lead to liver damage, cirrhosis, and liver cancer.

3. **Kidney Diseases**: HIV-associated nephropathy and other kidney-related issues can arise due to the virus itself or the medications used to treat HIV.

4. **Mental Health Disorders**: Depression, anxiety, and other mental health issues are prevalent among PLHIV, often exacerbated by stigma, social isolation, and the challenges of managing a chronic illness.

5. **Neurological Disorders**: HIV can affect the central nervous system, leading to conditions such as HIV-associated neurocognitive disorders (HAND), peripheral neuropathy, and other neurological complications.

6. **Cancers**: PLHIV have an increased risk of certain cancers, including Kaposi's sarcoma, lymphomas, and cervical cancer, often due to immunosuppression and coinfections with oncogenic viruses.

7. **Respiratory Conditions**: Increased risk of respiratory infections, such as pneumonia, and chronic lung conditions like chronic obstructive pulmonary disease (COPD) due to smoking and other factors.

8. **Metabolic Disorders**: HIV and its treatments can lead to metabolic issues such as lipodystrophy, insulin resistance, and dyslipidemia, which can increase the risk of diabetes and cardiovascular disease.

9. **Bone Health Issues**: Osteoporosis and other bone density issues can arise due to the effects of HIV and certain medications on bone metabolism.

10. **Gastrointestinal Disorders**: Conditions such as gastrointestinal infections, nausea, and diarrhea can be common, often related to HIV itself or the medications used for treatment.

11. **Age-Related Conditions**: As PLHIV age, they may experience age-related comorbidities at a younger age compared to the general population, including conditions like arthritis and age-related cognitive decline.

Managing these comorbidities often requires a comprehensive approach that includes regular monitoring, appropriate medications, lifestyle modifications, and support for mental health.
Starting inference for question (NVLM): How can HIV be prevented?
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
HIV (Human Immunodeficiency Virus) is a virus that attacks the body's immune system. If not treated, it can lead to AIDS (Acquired Immunodeficiency Syndrome). Here are some ways to prevent HIV:

1. **Abstain from sexual activity**: Not having sex is the most reliable way to avoid HIV transmission.

2. **Use condoms**: Consistent and correct use of latex or polyurethane condoms during vaginal, anal, and oral sex can significantly reduce the risk of HIV transmission.

3. **Limit sexual partners**: Reducing the number of sexual partners can lower the risk of exposure to HIV.

4. **Get tested**: Regular HIV testing is important, especially for those who are sexually active or at higher risk. Knowing one's HIV status can help prevent the spread of the virus.

5. **Pre-exposure prophylaxis (PrEP)**: PrEP is a daily medication that can be taken by HIV-negative individuals to significantly reduce the risk of acquiring HIV.

6. **Post-exposure prophylaxis (PEP)**: PEP is an emergency treatment that can be taken within 72 hours after potential exposure to HIV to prevent infection.

7. **Avoid sharing needles**: Do not share needles, syringes, or other drug injection equipment. If you inject drugs, use sterile needles and get help to stop using drugs.

8. **HIV treatment**: If you are HIV-positive, taking antiretroviral therapy (ART) as prescribed can lower the viral load to undetectable levels, which makes it very difficult to transmit the virus to others.

9. **Educate yourself and others**: Understanding how HIV is transmitted and the importance of prevention can help reduce stigma and promote healthy behaviors.

10. **Practice safe sex**: Engage in open communication with sexual partners about HIV status and safer sex practices.

By following these guidelines, individuals can significantly reduce their risk of contracting or transmitting HIV.
Starting inference for question (NVLM): How frequently ART must be taken?
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
Antiretroviral therapy (ART) is typically taken daily. The specific regimen and frequency can vary depending on the individual's health status, the medications prescribed, and other factors. It's important for individuals on ART to follow their prescribed regimen closely to ensure effectiveness and prevent drug resistance.
Starting inference for question (NVLM): How can we prevent Perinatal transmission of HIV?
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
Preventing perinatal transmission of HIV, which refers to the transmission of the virus from mother to child during pregnancy, childbirth, or breastfeeding, involves several key strategies:

1. **Prenatal Testing and Counseling**: Routine HIV testing during pregnancy is crucial. Early detection allows for timely intervention and treatment.

2. **Antiretroviral Therapy (ART)**: Pregnant women with HIV should receive antiretroviral therapy to reduce the viral load. Lower viral loads significantly decrease the risk of transmission to the baby.

3. **Safe Delivery Practices**: Elective cesarean delivery before the onset of labor and rupture of membranes can reduce the risk of transmission, especially if the mother's viral load is high.

4. **Avoiding Breastfeeding**: In settings where safe alternatives to breastfeeding are available, avoiding breastfeeding is recommended to prevent postnatal transmission of HIV.

5. **Infant Prophylaxis**: Newborns of HIV-positive mothers can receive antiretroviral prophylaxis to reduce the risk of infection.

6. **Regular Monitoring**: Close monitoring of both the mother and the infant after birth is essential to manage any potential health issues and to ensure that the infant receives appropriate care.

7. **Education and Support**: Providing education and support to HIV-positive mothers about their condition, treatment options, and the importance of adherence to therapy can help in preventing transmission.

8. **Access to Healthcare**: Ensuring that pregnant women have access to quality healthcare services, including prenatal care, is vital for effective prevention strategies.

By implementing these strategies, the risk of perinatal transmission of HIV can be significantly reduced, allowing for healthier outcomes for both mothers and their infants.
Starting inference for question (NVLM): What are the main cell types infected with HIV?
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
HIV primarily infects CD4+ T cells and macrophages.
Starting inference for question (NVLM): What is the difference between HIV and AIDS?
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
HIV (Human Immunodeficiency Virus) and AIDS (Acquired Immunodeficiency Syndrome) are related but distinct terms. Here’s a breakdown of the differences:

1. **HIV**:
   - **Nature**: HIV is a virus that infects the immune system, specifically targeting CD4 cells (T cells), which are crucial for fighting infections.
   - **Transmission**: It is primarily transmitted through sexual contact, sharing needles, or from mother to child during pregnancy, childbirth, or breastfeeding.
   - **Symptoms**: In the early stages, some people may experience flu-like symptoms, but many may not show any symptoms for years. HIV can progress through different stages: acute HIV infection, clinical latency, and AIDS.
   - **Treatment**: Antiretroviral therapy (ART) can effectively manage HIV, allowing individuals to live long, healthy lives. With proper treatment, the viral load can be reduced to undetectable levels.

2. **AIDS**:
   - **Definition**: AIDS is a syndrome that occurs when HIV has severely damaged the immune system, leading to a specific set of symptoms and opportunistic infections.
   - **Criteria**: A person is diagnosed with AIDS when their CD4 cell count drops below 200 cells/mm³ or when they develop certain opportunistic infections or cancers.
   - **Symptoms**: Common symptoms include weight loss, fever, night sweats, and increased susceptibility to infections.
   - **Prognosis**: Without treatment, the prognosis for individuals with AIDS is poor, but with ART, many can return to a healthier state and manage the condition effectively.

In summary, HIV is the virus that can lead to AIDS if left untreated. AIDS is a stage of HIV infection characterized by significant immune system damage and specific health conditions.
Starting inference for question (NVLM): How is HIV not transmitted?
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
HIV (Human Immunodeficiency Virus) is not transmitted through casual contact, such as hugging, shaking hands, or sharing personal items like utensils or toilets. It cannot be spread through air, water, or food. HIV is also not transmitted through mosquito bites or other insect bites. The virus is primarily spread through certain bodily fluids from a person who has HIV, including semen, vaginal fluids, rectal fluids, breast milk, and blood. Transmission occurs through specific activities, such as unprotected sexual intercourse, sharing needles or syringes, or from mother to child during pregnancy, childbirth, or breastfeeding. Understanding these modes of transmission helps in preventing the spread of HIV.
Starting inference for question (NVLM): What is known about the switch that occurs between
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
The switch between latent HIV and active infection is not fully understood, but it is known that it involves a complex interplay of factors. Latent HIV, also known as the latent reservoir, is a state where the virus is present in the body but is not actively replicating or causing symptoms. This reservoir is a major barrier to curing HIV, as it allows the virus to persist even when antiretroviral therapy (ART) is effective in suppressing active infection.

Several factors can contribute to the activation of latent HIV:

1. **Immune System Changes**: The immune system plays a crucial role in controlling HIV. Changes in immune cell activation, inflammation, and the presence of certain immune signals can lead to the reactivation of latent HIV.

2. **Cellular Activation**: HIV primarily infects CD4+ T cells, which are a type of white blood cell. When these cells are activated, they can produce new viruses, leading to active infection.

3. **Epigenetic Modifications**: The HIV virus can integrate into the host genome and remain latent due to epigenetic modifications that silence its expression. Factors that alter these modifications can lead to the reactivation of the virus.

4. **Environmental Factors**: Certain infections, stress, or other external factors can trigger the immune system and lead to the reactivation of latent HIV.

Understanding this switch is crucial for developing strategies to eliminate the latent reservoir and potentially cure HIV. Ongoing research is focused on identifying the specific mechanisms that control this transition and developing therapies that can safely reactivate and eliminate latent HIV.
Saved NVLM answers (category=1, iteration=1) to: /cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/model_answers/raw/NVLM/NVLM_answers_category_1.1_HIV_EQ.json
Starting inference for question (NVLM): A 58-year-old woman with HIV infection is brought 
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
The most likely diagnosis in this case is Primary Central Nervous System Lymphoma (PCNSL). 

Here's the reasoning behind this conclusion:

1. **Patient History and Symptoms**: The patient is a 58-year-old woman with HIV infection, which is a known risk factor for developing certain types of lymphomas, including PCNSL. Her symptoms of headaches, blurred vision, and confusion, along with neurological findings such as ataxia and memory impairment, suggest a central nervous system (CNS) pathology.

2. **Immunocompromised State**: With a CD4+ T-lymphocyte count of 90/μL, the patient is immunocompromised, which increases the risk of opportunistic infections and malignancies, including lymphomas.

3. **CSF Analysis**: The presence of lymphocytic predominant pleocytosis in the cerebrospinal fluid (CSF) is consistent with an inflammatory process or malignancy affecting the CNS.

4. **PCR for Epstein-Barr Virus (EBV)**: The positive PCR for EBV DNA is significant because EBV is often associated with certain types of lymphomas, including PCNSL.

5. **MRI Findings**: The MRI showing a solitary, weakly ring-enhancing lesion with well-defined borders involving the corpus callosum is characteristic of PCNSL. Ring-enhancing lesions are often seen in primary brain tumors, and the location in the corpus callosum is consistent with PCNSL.

6. **Differential Diagnosis**: While other conditions such as toxoplasmosis or other opportunistic infections could present with similar findings, the combination of the patient's immunocompromised status, specific MRI findings, and the presence of EBV DNA strongly supports the diagnosis of PCNSL.

In summary, the clinical presentation, laboratory findings, and imaging results collectively point towards a diagnosis of Primary Central Nervous System Lymphoma.
Starting inference for question (NVLM): A 25-year-old sexually active male presents to an 
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
The medication that acts on the gp41 subunit of the HIV envelope glycoprotein is called an entry inhibitor, specifically a fusion inhibitor. The most well-known fusion inhibitor is **Maraviroc** (Selzentry). This class of drugs prevents the HIV virus from entering and fusing with the host cells, thereby inhibiting the infection process.
Starting inference for question (NVLM): A mother with HIV has given birth to a healthy boy
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
If the mother boiled the formula longer than necessary, the heat could inactivate certain nutrients, particularly heat-sensitive vitamins like Vitamin C. Vitamin C is an important antioxidant and plays a crucial role in various molecular processes, including:

1. **Antioxidant Function**: Vitamin C helps protect cells from damage caused by free radicals, which can lead to oxidative stress and contribute to various diseases.

2. **Collagen Synthesis**: Vitamin C is essential for the synthesis of collagen, a protein that provides structure to skin, bones, and connective tissues.

3. **Iron Absorption**: Vitamin C enhances the absorption of non-heme iron (found in plant-based foods) in the gastrointestinal tract.

4. **Immune Function**: Vitamin C supports the immune system by promoting the function of immune cells.

5. **Synthesis of Neurotransmitters**: Vitamin C is involved in the synthesis of certain neurotransmitters, which are crucial for nerve signal transmission.

If the formula is overheated, the molecular structure of Vitamin C can be altered, leading to its inactivation and reducing its availability for these important biological functions. This could potentially impact the child's overall health and development, particularly in the early stages of life when adequate nutrition is critical.
Starting inference for question (NVLM): A 35-year-old woman presents to a physician’s offi
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
After resolving acute pancreatitis, the patient's treatment regimen, including her combination antiretroviral therapy (cART) for HIV, will need to be carefully managed. Here are some precautions and considerations that should be taken into account:

1. **Medication Review**: A thorough review of her current medications, including zidovudine, didanosine, and efavirenz, should be conducted to assess their potential impact on pancreatic function and any contraindications.

2. **Monitoring for Side Effects**: The patient should be closely monitored for any side effects of her medications, particularly those that may exacerbate gastrointestinal issues or have metabolic implications. Didanosine, for example, can cause gastrointestinal upset, and zidovudine can lead to lactic acidosis, which may be of concern in a patient with recent pancreatitis.

3. **Dose Adjustment**: Depending on the severity of her pancreatitis and her overall health, adjustments to the doses of her medications may be necessary. This is particularly important if she has any renal or hepatic impairment, as these organs play a role in drug metabolism and excretion.

4. **Nutritional Support**: Post-pancreatitis, the patient may require nutritional support, especially if she has nausea, vomiting, or difficulty tolerating oral intake. This should be coordinated with her HIV treatment to ensure adequate nutrition and medication absorption.

5. **Regular Follow-Up**: The patient should have regular follow-up appointments to monitor her HIV viral load, CD4 count, and overall health. This will help in assessing the effectiveness of her treatment and making any necessary adjustments.

6. **Patient Education**: Educating the patient about the importance of adherence to her medication regimen, the potential side effects, and the need for regular monitoring will be crucial. She should also be advised on lifestyle modifications, such as avoiding alcohol and maintaining a healthy diet, which can help prevent future episodes of pancreatitis.

7. **Consideration of Alternative Therapies**: If the patient continues to experience gastrointestinal issues or if there are concerns about the tolerability of her current regimen, alternative antiretroviral medications may be considered. This should be done in consultation with an HIV specialist.

8. **Psychosocial Support**: Given her history of sexual behavior and recent diagnosis of HIV, psychosocial support should be offered to address any emotional or psychological concerns that may arise from her diagnosis and treatment.

By taking these precautions, the healthcare team can help ensure that the patient's HIV treatment is effective and safe while also managing the potential complications related to her history of pancreatitis.
Starting inference for question (NVLM): A physician scientist is looking for a more effici
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
The most likely target of the antibody the physician scientist is designing would be the HIV envelope glycoprotein, specifically gp120. This protein is a key component of the HIV envelope and is the primary target for neutralizing antibodies produced during the natural humoral immune response. Gp120 is responsible for binding to the CD4 receptor on host cells, which is a critical step in the viral entry process. Therefore, an antibody targeting gp120 could potentially block this interaction and prevent the virus from entering and infecting new cells, making it a highly relevant target for developing a more potent therapeutic antibody against HIV.
Starting inference for question (NVLM): A 50-year-old HIV-positive male presents to the ER
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
The most likely causal organism in this case is **Aspergillus species**, specifically *Aspergillus fumigatus*. The presence of septate hyphae that branch at acute angles is characteristic of Aspergillus, and the clinical presentation of fever and hemoptysis in an immunocompromised patient (HIV-positive) with a fibrocavitary lesion on chest radiograph strongly suggests an aspergillus infection, particularly Aspergillus fumigatus.
Starting inference for question (NVLM): A 43-year-old man with HIV infection comes to the 
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
Valganciclovir, an antiviral medication used to treat cytomegalovirus (CMV) infections, can lead to several adverse effects, particularly when added to an existing antiretroviral therapy regimen. The most significant adverse effects that the patient is at risk for include:

1. **Hematologic Toxicity**: Valganciclovir can cause neutropenia (low neutrophil counts), anemia, and thrombocytopenia (low platelet counts). Given that the patient is already on antiretroviral therapy, which can also have hematologic side effects, the risk of these complications may be heightened.

2. **Renal Toxicity**: Valganciclovir can cause nephrotoxicity, which may be exacerbated if the patient has pre-existing renal impairment or is taking other medications that affect kidney function.

3. **Bone Marrow Suppression**: The combination of valganciclovir with other antiretroviral agents can increase the risk of bone marrow suppression, leading to a further decrease in white blood cell counts and an increased risk of infections.

4. **Gastrointestinal Side Effects**: The patient may experience nausea, vomiting, or diarrhea, which could worsen his existing gastrointestinal symptoms.

5. **Drug Interactions**: Valganciclovir can interact with other medications the patient is taking, potentially leading to increased toxicity or reduced efficacy of the drugs.

Monitoring the patient closely for these adverse effects, particularly hematologic changes and renal function, will be essential during the course of treatment with valganciclovir.
Starting inference for question (NVLM): A 28-year-old G1P0 woman at 16 weeks estimated ges
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
The most appropriate diagnostic test to address the concern of HIV transmission to the baby would be to perform a **viral load test** on the newborn shortly after delivery. This test can detect the presence of HIV RNA in the baby's blood, providing a direct assessment of whether the virus has been transmitted. 

In addition to the viral load test, it is also important to perform an **HIV antibody test** on the newborn, but this test may not be reliable in the first few weeks of life due to the presence of maternal antibodies. Therefore, the viral load test is the more immediate and reliable method for detecting HIV in the newborn. 

It is crucial to initiate appropriate postnatal care and treatment for the mother and the newborn, including antiretroviral therapy (ART) for the mother during pregnancy and for the newborn after birth, to reduce the risk of transmission.
Starting inference for question (NVLM): A 32-year-old man comes to the office for a routin
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
The most appropriate next step for the physician in this situation is to engage in a sensitive and ethical discussion with the patient regarding the implications of his diagnosis and the importance of disclosure to his wife. The physician should explain the following points:

1. **Public Health Obligations**: The physician has a duty to protect public health and may be legally obligated to report certain infectious diseases, including HIV, to public health authorities. This is important for tracking and preventing the spread of the disease.

2. **Importance of Disclosure**: The physician should emphasize the importance of informing his wife about the diagnosis, as she may be at risk of exposure. This is crucial for her health and well-being, as she may need to be tested and potentially receive treatment or counseling.

3. **Support and Resources**: The physician should offer support and resources for the patient to help him navigate this difficult situation. This could include counseling services, support groups, or information on how to disclose the diagnosis to his wife in a sensitive manner.

4. **Confidentiality**: While respecting the patient's confidentiality, the physician should explain that there are limits to confidentiality when it comes to serious health risks to others. The physician should encourage open communication between the patient and his wife.

5. **Next Steps**: The physician should discuss the next steps in managing the patient's HIV, including further testing, treatment options, and the importance of regular follow-up.

Ultimately, the physician should encourage the patient to consider the well-being of his wife and the broader implications of nondisclosure, while also respecting his concerns and providing support throughout this process.
Starting inference for question (NVLM): A 41-year-old HIV-positive male presents to the ER
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
The patient's symptoms and the findings from the lumbar puncture suggest a diagnosis of cryptococcal meningitis, which is a common opportunistic infection in HIV-positive individuals. The encapsulated yeast with narrow-based buds seen on India ink staining is characteristic of Cryptococcus neoformans, the causative agent of this condition.

In addition to the findings from the lumbar puncture, the following diagnostic test results would also be expected in this patient:

1. **CSF Culture**: A culture of the cerebrospinal fluid (CSF) would likely grow Cryptococcus neoformans, confirming the diagnosis.

2. **Serum Cryptococcal Antigen Test**: A positive result for cryptococcal antigen in the serum would support the diagnosis of cryptococcal meningitis.

3. **CSF WBC Count**: An elevated white blood cell (WBC) count in the CSF, typically with a lymphocytic predominance, is common in cryptococcal meningitis.

4. **CSF Glucose Level**: As mentioned, a decreased CSF glucose level is a hallmark of cryptococcal meningitis, often below 40 mg/dL.

5. **CSF Protein Level**: An increased CSF protein level is also typical in this condition.

6. **Neuroimaging Studies**: MRI or CT scans of the brain may show signs of meningeal enhancement or other abnormalities consistent with meningitis.

7. **HIV Viral Load and CD4 Count**: The patient's HIV viral load may be high, and the CD4 count may be low, reflecting advanced HIV disease, which increases the risk of opportunistic infections like cryptococcal meningitis.

8. **Blood Culture**: While not typically positive in cryptococcal meningitis, blood cultures may be drawn to rule out other systemic infections.

These findings, taken together, would support the diagnosis of cryptococcal meningitis in the context of the patient's HIV status and clinical presentation.
Starting inference for question (NVLM):  What would be the best methodological approach to
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
Studying microRNAs (miRNAs) as therapeutic targets in HIV patients involves a multi-faceted approach that combines molecular biology, bioinformatics, and clinical research. Here’s a comprehensive methodological approach:

### 1. Literature Review and Hypothesis Generation
- **Review Existing Literature**: Conduct a thorough review of current literature on miRNAs in HIV pathogenesis, immune response, and latency.
- **Identify Key miRNAs**: Focus on miRNAs that have been implicated in HIV replication, immune modulation, or cellular processes relevant to HIV.

### 2. Sample Collection
- **Patient Cohorts**: Recruit a diverse cohort of HIV-positive patients, including those on antiretroviral therapy (ART) and those who are treatment-naïve. Collect blood samples, PBMCs (peripheral blood mononuclear cells), and other relevant tissues.
- **Control Groups**: Include HIV-negative individuals as controls to compare miRNA expression profiles.

### 3. miRNA Expression Profiling
- **Next-Generation Sequencing (NGS)**: Use small RNA sequencing to profile miRNA expression in patient samples. This allows for the identification of differentially expressed miRNAs between HIV-positive and control groups.
- **Quantitative PCR (qPCR)**: Validate findings from NGS using qPCR for specific miRNAs of interest, ensuring accurate quantification.

### 4. Bioinformatics Analysis
- **Data Analysis**: Use bioinformatics tools to analyze sequencing data, identify differentially expressed miRNAs, and perform pathway analysis to understand their biological roles.
- **Machine Learning**: Implement machine learning algorithms to predict miRNA targets and their potential impact on HIV-related pathways.

### 5. Functional Studies
- **In Vitro Models**: Use cell culture models (e.g., HIV-infected cell lines, primary T cells) to investigate the functional roles of identified miRNAs. This can include:
  - Overexpression or knockdown of specific miRNAs using mimics or inhibitors.
  - Assessment of HIV replication, immune cell activation, and cytokine production.

### 6. In Vivo Models
- **Animal Models**: Utilize animal models (e.g., HIV-susceptible mice or non-human primates) to study the effects of miRNA modulation on HIV infection and disease progression.
- **Therapeutic Interventions**: Test miRNA-based therapeutics (e.g., miRNA mimics or inhibitors) in these models to evaluate their efficacy and safety.

### 7. Clinical Trials
- **Pilot Studies**: Conduct small-scale clinical trials to assess the safety and feasibility of miRNA-based therapies in HIV patients.
- **Randomized Controlled Trials**: Design larger, randomized controlled trials to evaluate the efficacy of miRNA therapeutics in comparison to standard treatments.

### 8. Longitudinal Studies
- **Long-term Follow-up**: Monitor patients over time to assess the impact of miRNA modulation on viral load, CD4+ T cell counts, and overall health outcomes.

### 9. Ethical Considerations
- **Informed Consent**: Ensure that all participants provide informed consent, understanding the risks and benefits of the study.
- **Ethical Approval**: Obtain approval from institutional review boards (IRBs) for all aspects of the research involving human subjects.

### 10. Collaboration and Interdisciplinary Approach
- **Collaboration**: Work with virologists, immunologists, bioinformaticians, and clinical researchers to leverage diverse expertise.
- **Interdisciplinary Research**: Integrate findings from various fields to enhance understanding of miRNA roles in HIV and develop effective therapeutic strategies.

By following this structured approach, researchers can gain insights into the potential of miRNAs as therapeutic targets for HIV, ultimately aiming to improve treatment outcomes for patients.
Starting inference for question (NVLM): What is known about DNA methylation profiles in pa
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
In patients with latent HIV-1, DNA methylation profiles are associated with transcriptional silencing of the provirus. In contrast, patients with active HIV-1 infection exhibit DNA methylation profiles that are associated with transcriptional activation of the provirus.
Saved NVLM answers (category=3, iteration=1) to: /cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/model_answers/raw/NVLM/NVLM_answers_category_3.1_HIV_EQ.json
Starting inference for question (NVLM): A 26-year-old female with AIDS (CD4 count: 47) pre
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
In the acute setting, given the patient's presentation with severe headache, fever, fatigue, and the findings from the lumbar puncture (increased opening pressure, lymphocytes, elevated protein, and decreased glucose), it is likely that she is experiencing a opportunistic infection such as cryptococcal meningitis, which is common in patients with AIDS and low CD4 counts.

In addition to the treatment with IV amphotericin B and PO flucytosine, the following additional treatments may be warranted:

1. **Antiretroviral Therapy (ART)**: If the patient is not already on antiretroviral therapy, it should be initiated as soon as possible to improve her immune function and overall health.

2. **Corticosteroids**: If there is evidence of significant inflammation or cerebral edema, corticosteroids (such as dexamethasone) may be considered to reduce inflammation and intracranial pressure.

3. **Antiemetics**: If the patient is experiencing nausea or vomiting due to her symptoms, antiemetic medications (such as metoclopramide or ondansetron) may be necessary for symptom control.

4. **Pain Management**: For her severe pain, appropriate analgesics (such as acetaminophen or NSAIDs) may be necessary. If pain is refractory, opioids may be considered.

5. **Fluid Management**: Given the elevated opening pressure, careful fluid management is important to avoid exacerbating intracranial pressure.

6. **Monitoring and Supportive Care**: Close monitoring of her neurological status, vital signs, and laboratory values is essential. Supportive care, including hydration and nutritional support, should also be provided.

7. **Consultation with Infectious Disease Specialist**: Given the complexity of her case, consultation with an infectious disease specialist may be beneficial for ongoing management and treatment strategies.

8. **Neurological Evaluation**: If there are concerns about neurological deficits or worsening symptoms, a neurology consultation may be indicated for further evaluation and management.

By addressing these aspects, the patient's immediate needs can be met while also preparing for long-term management of her HIV and potential complications.
Starting inference for question (NVLM): You are reviewing raw data from a research study p
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
To calculate the Negative Predictive Value (NPV) of the novel AIDS screening examination, we need to use the following formula:

\[
\text{NPV} = \frac{\text{Number of True Negatives}}{\text{Number of True Negatives} + \text{Number of False Negatives}}
\]

From the data provided:

- **Total patients with AIDS (Positive group)**: 250
- **Positive screening results in the AIDS group**: 240
- **Total patients without AIDS (Negative group)**: 250
- **Positive screening results in the non-AIDS group**: 5

From this, we can determine the following:

1. **True Positives (TP)**: The number of patients with AIDS who tested positive. This is 240.
2. **False Negatives (FN)**: The number of patients with AIDS who tested negative. This is \(250 - 240 = 10\).
3. **True Negatives (TN)**: The number of patients without AIDS who tested negative. This is \(250 - 5 = 245\).
4. **False Positives (FP)**: The number of patients without AIDS who tested positive. This is 5.

Now we can calculate the NPV:

\[
\text{NPV} = \frac{\text{TN}}{\text{TN} + \text{FN}} = \frac{245}{245 + 10} = \frac{245}{255} \approx 0.9608
\]

To express this as a percentage, we multiply by 100:

\[
\text{NPV} \approx 96.08\%
\]

Thus, the Negative Predictive Value (NPV) of the novel AIDS screening examination is approximately **96.08%**.
Starting inference for question (NVLM): A 46-year-old Caucasian male with past medical his
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
Given the patient's sudden onset of right hand weakness, gradual worsening of symptoms, and the presence of other risk factors, the next best step in management would be to perform a comprehensive evaluation to determine the cause of the weakness. This should include the following:

1. **Neuroimaging**: Order an urgent brain MRI with contrast to evaluate for potential causes of the weakness, such as stroke, demyelinating disease, or other neurological conditions. A CT scan of the brain can be performed initially if MRI is not readily available.

2. **Laboratory Tests**: Conduct a complete blood count (CBC), comprehensive metabolic panel (CMP), HIV viral load, and CD4 count to assess his overall health and immune status. Additionally, consider testing for electrolytes, inflammation markers (e.g., CRP, ESR), and other relevant tests based on clinical findings.

3. **Neurological Consultation**: Given the neurological deficit, consult with a neurologist for further evaluation and management. The neurologist can provide expertise in interpreting imaging results and determining the need for additional diagnostic tests.

4. **Assessment for Infection**: Given the patient's HIV status and recent fever, assess for possible infections that could be contributing to his symptoms. This may include cultures and additional infectious disease consultations if indicated.

5. **Review of Medications**: Review the patient's medication adherence and assess for any potential drug interactions or side effects that could contribute to his symptoms.

6. **Monitoring and Supportive Care**: Monitor the patient closely for any changes in his neurological status and provide supportive care as needed, including pain management for his osteoarthritis.

By following these steps, the healthcare team can work towards identifying the underlying cause of the patient's weakness and initiate appropriate treatment.
Starting inference for question (NVLM): A 44-year-old man is brought to the emergency depa
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
The most likely diagnosis for the 44-year-old man with the described symptoms and findings is **HIV-associated neurocognitive disorder (HAND)**, specifically **HIV encephalitis**. 

Here’s the reasoning behind this diagnosis:

1. **HIV Infection**: The patient has a known history of HIV, and his CD4+ count is critically low (56/μL), indicating advanced immunodeficiency. This low CD4 count is a significant risk factor for developing neurological complications.

2. **Neurological Symptoms**: The patient presents with right leg weakness, unsteady gait, and cognitive impairments such as forgetfulness and difficulty with simple tasks. These symptoms are consistent with HIV encephalitis, which can lead to motor deficits and cognitive decline.

3. **Psychiatric Symptoms**: The patient's paranoia, agitation, and restlessness are also common in HIV encephalitis, often referred to as HIV-associated dementia (HAD) or HIV encephalopathy.

4. **Laboratory Findings**: The negative Cryptococcal antigen test rules out cryptococcal meningitis, which is another potential opportunistic infection in HIV patients. The positive Toxoplasma gondii IgG indicates past exposure but does not necessarily indicate active infection.

5. **MRI Findings**: The disseminated, nonenhancing white matter lesions on MRI are characteristic of HIV encephalitis and other HIV-related neurological complications.

Given the combination of the patient's HIV status, low CD4 count, neurological symptoms, and MRI findings, HIV encephalitis is the most likely diagnosis. It is crucial to initiate antiretroviral therapy (ART) promptly to manage his HIV and address his neurological symptoms.
Starting inference for question (NVLM): A 25-year-old nulliparous woman at 8 weeks' gestat
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
At the first prenatal visit for a 25-year-old nulliparous woman at 8 weeks' gestation, several tests and assessments are typically recommended to ensure a healthy pregnancy. Here are the tests that should be considered:

1. **Prenatal Blood Tests:**
   - **Complete Blood Count (CBC):** To assess overall health, check for anemia, and evaluate blood cell counts.
   - **Blood Type and Rh Factor:** To determine blood type and Rh status, which is important for potential Rh incompatibility issues.
   - **Hemoglobin and Hematocrit:** To screen for anemia.
   - **Rubella Immunity Test:** To check if she is immune to rubella (German measles), which can cause birth defects if contracted during pregnancy.
   - **Hepatitis B Surface Antigen (HBsAg):** To screen for hepatitis B infection.
   - **Hepatitis C Virus (HCV) Antibody Test:** To screen for hepatitis C infection.
   - **Syphilis Screening:** To test for syphilis, which can affect the baby if left untreated.
   - **HIV Screening:** Although she tested negative 4 years ago, it is recommended to retest during pregnancy due to the potential for transmission to the baby.

2. **Urine Tests:**
   - **Urinalysis:** To check for signs of infection, proteinuria, and glucose levels, which can indicate gestational diabetes or other issues.

3. **Physical Examination:**
   - A thorough physical examination, including a pelvic exam, to assess the reproductive system and check for any abnormalities.

4. **Ultrasound:**
   - An ultrasound may be performed to confirm the pregnancy, assess the gestational age, and check for the presence of a heartbeat.

5. **Genetic Screening:**
   - Discussion about options for genetic screening, including carrier screening for conditions like cystic fibrosis, sickle cell disease, and spinal muscular atrophy, especially if there is a family history of genetic disorders.

6. **Prenatal Counseling:**
   - Discussion about lifestyle modifications, nutrition, and any concerns the patient may have regarding her pregnancy.

7. **Vaccination Update:**
   - Assessment of her vaccination status, including the need for a tetanus, diphtheria, and pertussis (Tdap) booster during pregnancy.

8. **Screening for Domestic Violence:**
   - Routine screening for domestic violence, as it can affect the health of both the mother and the baby.

9. **Assessment of Psychosocial Factors:**
   - Evaluation of her emotional well-being and any psychosocial factors that may impact her pregnancy.

By conducting these tests and assessments, the healthcare provider can ensure a comprehensive evaluation of the mother's health and the health of the developing fetus, allowing for early intervention if any issues arise.
Starting inference for question (NVLM): A 33-year-old HIV-positive male is seen in clinic 
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
In addition to anti-retroviral therapy (ART), the patient should consider taking medications to address his depression, which may help improve adherence to his HIV medications. Commonly prescribed antidepressants include selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, sertraline, or escitalopram. It is important to consult with a healthcare provider to determine the most appropriate medication based on the patient's specific circumstances, potential side effects, and interactions with his current ART regimen. Additionally, the patient may benefit from counseling or psychotherapy to address his depression and improve overall mental health.
Starting inference for question (NVLM): A 30-year-old woman with HIV comes to the emergenc
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
The patient's presentation, including her HIV status, low CD4+ T-lymphocyte count, and the characteristics of her skin lesions, strongly suggests a diagnosis of Kaposi's sarcoma (KS). The presence of vascular proliferation in the skin biopsy and the low CD4 count are indicative of KS, which is a common opportunistic infection in HIV-positive individuals, especially those with advanced immunodeficiency.

Given the diagnosis of Kaposi's sarcoma, the most appropriate pharmacotherapy would be to initiate treatment with a systemic chemotherapy agent that is effective against KS. The first-line treatment for KS in HIV-positive patients is typically a combination of antiretroviral therapy (ART) to improve immune function and chemotherapy to target the KS lesions.

1. **Antiretroviral Therapy (ART)**: The patient should be started on an appropriate ART regimen to manage her HIV infection and improve her CD4 count. This is crucial for overall health and to reduce the risk of further opportunistic infections.

2. **Chemotherapy for KS**: Commonly used agents for KS include:
   - **Liposomal doxorubicin**: This is often the first-line treatment for KS due to its efficacy and manageable side effect profile.
   - **Paclitaxel**: This can also be effective, especially in cases where liposomal doxorubicin is contraindicated or not tolerated.

3. **Supportive Care**: The patient should also receive supportive care for her symptoms, including management of nausea and abdominal pain. This may include antiemetics and analgesics as needed.

4. **Monitoring**: Close monitoring of her response to treatment, including regular CD4 counts and viral load measurements, is essential. Additionally, monitoring for side effects of chemotherapy is important.

In summary, the most appropriate pharmacotherapy for this patient would be to initiate an appropriate ART regimen and start chemotherapy with liposomal doxorubicin or paclitaxel, while also providing supportive care for her symptoms.
Starting inference for question (NVLM): A 35-year-old man comes to the physician because o
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
The patient, a 35-year-old man with a positive HIV test, is being treated with a combination of antiretroviral medications: lamivudine, zidovudine, and indinavir. Each of these drugs has specific adverse effects that the patient may be at risk for:

1. **Lamivudine**: Common side effects include nausea, diarrhea, and headache. Less commonly, it can lead to liver problems, especially in patients with pre-existing liver conditions.

2. **Zidovudine**: This medication can cause a range of side effects, including nausea, vomiting, diarrhea, and fatigue. More serious side effects can include bone marrow suppression (leading to anemia, neutropenia, or thrombocytopenia), and lactic acidosis, which is a rare but serious metabolic complication.

3. **Indinavir**: This protease inhibitor can cause gastrointestinal side effects such as nausea, vomiting, and diarrhea. It can also lead to kidney stones and crystalluria (crystals in the urine), which can cause pain and urinary tract issues. Additionally, indinavir can interact with other medications and has been associated with lipodystrophy (changes in body fat distribution) and hyperlipidemia (high cholesterol).

Given the combination of these medications, the patient is at greatest risk for gastrointestinal adverse effects (nausea, vomiting, diarrhea), as well as potential hematologic issues (like anemia) from zidovudine and renal complications from indinavir. Close monitoring of his blood counts, liver function, and renal function will be important during the course of treatment.
Starting inference for question (NVLM): A 52-year-old man is brought to the emergency depa
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
The most likely diagnosis for the 52-year-old man with HIV, given his symptoms and findings, is ** Progressive Multifocal Leukoencephalopathy (PML)**. 

Here's the reasoning:

1. **Clinical Presentation**: The patient presents with headaches, vertigo, and changes in personality, which are common symptoms of PML. The neurological examination showing ataxia and apathy further supports this diagnosis.

2. **HIV and Immunosuppression**: The patient has a long history of HIV and has been on antiretroviral therapy. His CD4+ T-lymphocyte count is 90/μL, indicating significant immunosuppression, which is a risk factor for developing PML.

3. **MRI Findings**: The MRI shows a solitary ring-enhancing lesion in the corpus callosum, which is characteristic of PML. The size and location of the lesion are consistent with this diagnosis.

4. **CSF Analysis**: The slight pleocytosis in the cerebrospinal fluid (CSF) and the positive PCR for Epstein-Barr virus DNA suggest an active infection, which can be associated with PML, although the presence of EBV does not confirm PML.

5. **Exclusion of Other Diagnoses**: While other conditions such as primary central nervous system lymphoma or toxoplasmosis could also present with similar findings, the combination of the patient's HIV status, low CD4 count, and the specific MRI findings strongly point towards PML.

In summary, the clinical presentation, laboratory results, and imaging findings collectively support a diagnosis of Progressive Multifocal Leukoencephalopathy.
Starting inference for question (NVLM): A 2300-g (5-lb 1-oz) male newborn is delivered to 
Setting `pad_token_id` to `eos_token_id`:None for open-end generation.
The most appropriate next step in the management of this infant, given the mother's HIV status and the newborn's exposure, is to initiate post-exposure prophylaxis (PEP) for the newborn. This typically involves administering a combination of antiretroviral medications to the infant to reduce the risk of HIV transmission. Additionally, the infant should be closely monitored for signs of infection and undergo HIV testing at regular intervals, starting with an early infant diagnosis test, usually within the first few weeks of life.
Saved NVLM answers (category=4, iteration=1) to: /cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/model_answers/raw/NVLM/NVLM_answers_category_4.1_HIV_EQ.json
API call for Llama failed with error: Connection error.
Falling back to local Llama inference - Loading model...
Loading checkpoint shards:   0%|                                                              | 0/30 [00:00<?, ?it/s]Loading checkpoint shards:   3%|█▊                                                    | 1/30 [01:02<30:13, 62.52s/it]Loading checkpoint shards:   7%|███▌                                                  | 2/30 [01:44<23:27, 50.26s/it]Loading checkpoint shards:  10%|█████▍                                                | 3/30 [02:38<23:26, 52.11s/it]Loading checkpoint shards:  13%|███████▏                                              | 4/30 [02:47<15:14, 35.18s/it]Loading checkpoint shards:  17%|█████████                                             | 5/30 [03:19<14:09, 34.00s/it]Loading checkpoint shards:  20%|██████████▊                                           | 6/30 [04:20<17:19, 43.30s/it]Loading checkpoint shards:  23%|████████████▌                                         | 7/30 [04:27<12:01, 31.38s/it]Loading checkpoint shards:  27%|██████████████▍                                       | 8/30 [04:33<08:29, 23.17s/it]Loading checkpoint shards:  30%|████████████████▏                                     | 9/30 [04:45<06:50, 19.55s/it]Loading checkpoint shards:  33%|█████████████████▋                                   | 10/30 [04:52<05:13, 15.68s/it]Loading checkpoint shards:  37%|███████████████████▍                                 | 11/30 [06:02<10:18, 32.56s/it]Loading checkpoint shards:  40%|█████████████████████▏                               | 12/30 [06:08<07:16, 24.25s/it]Loading checkpoint shards:  43%|██████████████████████▉                              | 13/30 [06:50<08:26, 29.77s/it]Loading checkpoint shards:  47%|████████████████████████▋                            | 14/30 [07:26<08:25, 31.60s/it]Loading checkpoint shards:  50%|██████████████████████████▌                          | 15/30 [08:23<09:47, 39.19s/it]Loading checkpoint shards:  53%|████████████████████████████▎                        | 16/30 [08:30<06:54, 29.60s/it]Loading checkpoint shards:  57%|██████████████████████████████                       | 17/30 [08:34<04:44, 21.89s/it]Loading checkpoint shards:  60%|███████████████████████████████▊                     | 18/30 [08:57<04:26, 22.20s/it]Loading checkpoint shards:  63%|█████████████████████████████████▌                   | 19/30 [09:12<03:40, 20.05s/it]Loading checkpoint shards:  67%|███████████████████████████████████▎                 | 20/30 [09:12<02:21, 14.14s/it]Loading checkpoint shards:  70%|█████████████████████████████████████                | 21/30 [09:13<01:29,  9.96s/it]Loading checkpoint shards:  73%|██████████████████████████████████████▊              | 22/30 [09:13<00:56,  7.05s/it]Loading checkpoint shards:  77%|████████████████████████████████████████▋            | 23/30 [09:14<00:36,  5.20s/it]Loading checkpoint shards:  80%|██████████████████████████████████████████▍          | 24/30 [09:14<00:22,  3.71s/it]Loading checkpoint shards:  83%|████████████████████████████████████████████▏        | 25/30 [09:16<00:16,  3.24s/it]Loading checkpoint shards:  87%|█████████████████████████████████████████████▉       | 26/30 [09:18<00:11,  2.78s/it]Loading checkpoint shards:  90%|███████████████████████████████████████████████▋     | 27/30 [09:20<00:07,  2.52s/it]Loading checkpoint shards:  93%|█████████████████████████████████████████████████▍   | 28/30 [09:20<00:03,  1.83s/it]Loading checkpoint shards:  97%|███████████████████████████████████████████████████▏ | 29/30 [09:22<00:01,  1.86s/it]Loading checkpoint shards: 100%|█████████████████████████████████████████████████████| 30/30 [09:22<00:00,  1.37s/it]Loading checkpoint shards: 100%|█████████████████████████████████████████████████████| 30/30 [09:22<00:00, 18.75s/it]
Some parameters are on the meta device because they were offloaded to the cpu.
Starting inference for question locally (Llama): How is HIV diagnosed?
slurmstepd: error: *** STEP 21171624.0 ON eu-a65-06 CANCELLED AT 2025-01-18T19:04:19 DUE TO TIME LIMIT ***
slurmstepd: error: *** JOB 21171624 ON eu-a65-06 CANCELLED AT 2025-01-18T19:04:19 DUE TO TIME LIMIT ***
W0118 19:04:19.587000 22878650922816 torch/distributed/elastic/agent/server/api.py:741] Received 15 death signal, shutting down workers
W0118 19:04:19.587000 22878650922816 torch/distributed/elastic/multiprocessing/api.py:851] Sending process 3618003 closing signal SIGTERM
W0118 19:04:19.588000 22878650922816 torch/distributed/elastic/multiprocessing/api.py:851] Sending process 3618003 closing signal SIGTERM
